Novonesis A/S (NVZMY) & The Competition Head-To-Head Review

Novonesis A/S (OTC:NVZMY) is one of 297 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Novonesis A/S to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.

Institutional & Insider Ownership

0.0% of Novonesis A/S shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.9% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Novonesis A/S and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novonesis A/S	1	0	0	0	1.00
Novonesis A/S Competitors	1854	5247	13594	286	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 77.60%. Given Novonesis A/S’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Novonesis A/S has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Novonesis A/S and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novonesis A/S	$2.60 billion	$439.08 million	35.89
Novonesis A/S Competitors	$607.47 million	-$34.54 million	2.74

Novonesis A/S has higher revenue and earnings than its rivals. Novonesis A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Dividends

Novonesis A/S pays an annual dividend of $0.66 per share and has a dividend yield of 1.2%. Novonesis A/S pays out 41.8% of its earnings in the form of a dividend. As a group, “Biological products, except diagnostic” companies pay a dividend yield of 2.4% and pay out 116.4% of their earnings in the form of a dividend.

Profitability

This table compares Novonesis A/S and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novonesis A/S	N/A	N/A	N/A
Novonesis A/S Competitors	-2,205.44%	-140.07%	-40.26%

Volatility and Risk

Novonesis A/S has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Novonesis A/S’s rivals have a beta of 1.03, meaning that their average share price is 3% more volatile than the S&P 500.

Summary

Novonesis A/S rivals beat Novonesis A/S on 8 of the 15 factors compared.

About Novonesis A/S

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.